Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Therapy for Recurrent Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Recurrent unipolar major depressive disorder~* Have experienced at least two episodes of major depression~* Have experienced at least one period of recovery during a depressive episode or have a history of dysthymia (a mood disorder characterized by depression) prior to the onset of current or past depressive episodes~* Willing and able to comply with all study requirements~* Able to speak and read English~Exclusion Criteria:~* Active alcohol or other substance dependence within 6 months prior to study entry~* Currently at risk for suicide~* Mood disorders due to a medical condition or substance abuse~* Bipolar, schizoaffective, obsessive compulsive, or eating disorders~* Schizophrenia~* Unable to stop mood-altering medications~* Current use of medication or diagnosis of a medical disorder that may cause depression (e.g., diabetes, head injury, stroke, cancer, multiple sclerosis)~* Previous failure to experience a reduction in depressive symptoms after 8 weeks of cognitive therapy with a certified therapist~* Previous failure to experience a reduction in depressive symptoms after 6 weeks of 40 mg of Prozac~* Pregnancy or plan to become pregnant in the next 11-12 months~* Unable to attend clinic twice weekly during business hours~* Unable to complete questionnaires

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants received acute phase and continuation phase cognitive therapy
- 2 (Type: PLACEBO_COMPARATOR): Participants received acute phase cognitive therapy and continuation phase pill placebo
- 3 (Type: ACTIVE_COMPARATOR): Participants received acute phase cognitive therapy and continuation phase fluoxetine

Based on this trial design, predict the completion outcome and termination type (if applicable).